| RANBAXY LABORATORIES LIMITED Patent applications |
| Patent application number | Title | Published |
|---|
| 20130123511 | PROCESS FOR THE DIRECT PREPARATION OF MALIC ACID SALT OF SUNITINIB - The present invention relates to a process for the direct preparation of malic acid salt of sunitinib. | 05-16-2013 |
| 20130085304 | PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE - The present invention relates to processes for the preparation of crystalline polymorphic forms of lacosamide (Formula I), including processes for inter-conversion among such polymorphic forms. | 04-04-2013 |
| 20130085277 | PROCESS FOR THE PREPARATION OF BORTEZOMIB - The present invention relates to a process for the preparation of bortezomib (Formula I) and its intermediates. | 04-04-2013 |
| 20130072681 | PROCESS FOR STEREOSELECTIVE SYNTHESIS OF 5-FLUORO-1-(2R,5S)-[2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]CYTOSINE - The present invention provides an improved process for stereoselective preparation of 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine and pharmaceutically acceptable salts thereof. | 03-21-2013 |
| 20120329831 | PHARMACEUTICAL COMPOSITION OF DONEPEZIL - The present invention relates to a pharmaceutical composition of donepezil or pharmaceutically acceptable salts thereof comprising ethyl cellulose and methacrylic acid copolymer in a ratio of more than 1.3. Further, it relates to process for preparation of said composition. | 12-27-2012 |
| 20120309842 | PROCESSES FOR THE PREPARATION OF CINACALCET - The present invention provides processes and intermediates for preparing cinacalcet base and pharmaceutically acceptable salts thereof. | 12-06-2012 |
| 20120302749 | PROCESSES FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE FORM A AND ERLOTINIB HYDROCHLORIDE FORM B - The present invention relates to processes for the preparation of erlotinib hydrochloride Form A and erlotinib hydrochloride Form B. (I). | 11-29-2012 |
| 20120288532 | MULTI-LAYERED, MULTIPLE UNIT PHARMACEUTICAL COMPOSITIONS - The invention relates to pharmaceutical compositions comprising multilayered multiple units and processes for the preparation thereof. | 11-15-2012 |
| 20120283440 | CRYSTALLINE FORMS OF BOSENTAN SALTS AND PROCESSES FOR THEIR PREPARATION - The present invention relates to crystalline forms of bosentan salts and processes for their preparation.(FORMULA) | 11-08-2012 |
| 20120282333 | DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF MESALAMINE - The invention relates to a delayed release pharmaceutical composition of mesalamine comprising: a) granules comprising mesalamine or pharmaceutically acceptable salts thereof and a hydrophilic polymer; b) extragranular excipients; wherein the pharmaceutical composition is further coated with a single layer of polymer. | 11-08-2012 |
| 20120277426 | PROCESS FOR THE PREPARATION OF CRYSTALLINE APREPITANT HAVING FORM I CONTENT - The present invention provides a process for preparation of crystalline aprepitant having not more than 15% by weight of Form I content which comprises, a) dissolving aprepitant in a suitable solvent to obtain a solution, b) cooling the solution to 10-15° C., c) optionally seeding the solution with aprepitant Form I crystals, d) adding an anti-solvent to the solution, and e) isolating crystalline aprepitant having not more than 15% by weight of Form I content. | 11-01-2012 |
| 20120271056 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM I OF L-MALIC ACID SALT OF SUNITINIB - The present invention relates to a process for the preparation of crystalline Form I of the L-malic acid salt of sunitinib. | 10-25-2012 |
| 20120267533 | PROCESSES FOR THE PREPARATION OF FORM I AND FORM II OF PALONOSETRON HYDROCHLORIDE - The present invention relates to processes for the preparation of Form I and Form II of palonosetron hydrochloride. The present invention further relates to a method of determining the polymorphic forms of palonosetron hydrochloride using Fourier-Transform Infra-red (FTIR) method. | 10-25-2012 |
| 20120264789 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS - The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib. | 10-18-2012 |
| 20120259014 | TOPICAL RETNOID SOLUTIONS - The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and a process of preparing it. | 10-11-2012 |
| 20120259013 | LIQUID DOSAGE FORMS OF ISOTRETINOIN - The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions. | 10-11-2012 |
| 20120220786 | PROCESS FOR THE PREPARATION OF FOSAMPRENAVIR CALCIUM - The present invention relates to process for the preparation of fosamprenavir calcium. | 08-30-2012 |
| 20120220783 | SALTS OF SUNITINIB - The present invention relates to salts of sunitinib and their preparation. | 08-30-2012 |
| 20120220777 | PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF LENALIDOMIDE - The present invention relates to an in-situ process for the preparation of polymorphic Form A of lenalidomide. | 08-30-2012 |
| 20120208787 | CRYSTALLINE FORM OF FOSAMPRENAVIR CALCIUM - The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to a pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium. The present invention relates further to a method of treating a HIV infection using crystalline Form II of fosamprenariv calium. | 08-16-2012 |
| 20120190850 | PROCESS FOR THE PREPARATION OF VALGANCICLOVIR HYDROCHLORIDE - The present invention provides a novel process for the preparation of pure valganciclovir hydrochloride. | 07-26-2012 |
| 20120190849 | PROCESSES FOR THE PREPARATION OF VARDENAFIL - The present invention provides processes for the preparation of vardenafil, its pharmaceutically acceptable salts, hydrates and intermediates. | 07-26-2012 |
| 20120184751 | POLYMORPHIC FORM OF OLMESARTAN MEDOXOMIL - The present invention relates to a polymorphic form of olmesartan medoxomil and a process for the preparation of crystalline olmesartan medoxomil. | 07-19-2012 |
| 20120184750 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL - The present invention provides an improved process for the preparation of olmesartan medoxomil, which is free of OLM-acid and has lower amount of eliminate and acetic acid impurity. | 07-19-2012 |
| 20120184746 | PROCESS FOR THE PREPARATION OF LENALIDOMIDE - The present invention relates to a process for the preparation of lenalidomide, wherein the process comprises: reducing 3-(4-nitro-loxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione to obtain lenalidomide. | 07-19-2012 |
| 20120183607 | STABLE DOSAGE FORMS OF SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS - The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w. | 07-19-2012 |
| 20120178944 | PROCESS FOR THE PREPARATION OF 1, 2, 4-TRIOXOLANE ANTIMALARIALS - This invention relates to an improved process for the preparation of compounds of Formula I, salts of the free base cis-adamantane-2-spiro-3′-8′-[[[(2′-amino-2′-methyl propyl)amino]carbonyl]methyl]-1′,2′,4′-trioxaspiro[4.5]decane, Formula (I) wherein X is an anion. The compounds of Formula (I) have antimalarial activity. | 07-12-2012 |
| 20120178821 | POLYMORPHIC FORM OF TOREMIFENE CITRATE AND PROCESS FOR ITS PREPARATION - The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharmaceutically acceptable salts. | 07-12-2012 |
| 20120165386 | STABLE ORAL PHARMACEUTIAL COMPOSITION OF ATORVASTATIN - The present invention relates to a stable oral pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof and an alkalizing agent, wherein the buffering capacity of the composition is between 2 to 5. | 06-28-2012 |
| 20120164233 | PULSATILE RELEASE PHARMACEUTICAL FORMULATION OF DEXLANSOPRAZOLE - The present invention relates to a pulsatile-release pharmaceutical formulation of dexlansoprazole composed of a single type of enteric coated pellets and the process for the preparation thereof. | 06-28-2012 |
| 20120149720 | VALACYCLOVIR FORMULATIONS - The present invention relates to taste-masked pharmaceutical formulations of valacyclovir. The present invention also relates to process of preparation of valacyclovir suspensions, solutions and dry powder for reconstitution. | 06-14-2012 |
| 20120135965 | AMORPHOUS FOSAMPRENAVIR CALCIUM - The present invention relates to amorphous Fosamprenavir calcium and processes for its preparation, a pharmaceutical composition comprising it and a method for treating a HIV infection therewith. | 05-31-2012 |
| 20120107424 | ANTI DENGUE ACTIVITY OF CISSAMPELOS PAREIRA EXTRACTS - The present invention relates to the anti dengue activity of the | 05-03-2012 |
| 20120101281 | PROCESS FOR THE PREPARATION OF DESLORATADINE - The present invention provides a process for the preparation of desloratadine comprising contacting loratadine with a mixture of a weak inorganic base and sodium or potassium hydroxide in a ratio, ranging from 0.01 to 0.15 equivalents of sodium or potassium hydroxide per equivalent of weak inorganic base, in one or more suitable solvents) followed by isolation. | 04-26-2012 |
| 20120101272 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a nove-ICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate. | 04-26-2012 |
| 20120100221 | PHARMACEUTICAL COMPOSITIONS CONTAINING A COMBINATION OF AN ANTIHISTAMINE AND A DECONGESTANT - This invention relates to a layered pharmaceutical composition comprising a combination of an antihistamine and a decongestant. | 04-26-2012 |
| 20120093928 | ORAL METAXALONE COMPOSITIONS - The present invention relates to a pharmaceutical composition comprising low-dose metaxalone and one or more pharmaceutically acceptable polymer, as well as methods of preparing them. | 04-19-2012 |
| 20120093878 | PHARMACEUTICAL COMPOSITIONS CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE - The present invention relates to pharmaceutical compositions that include a combination of a biguanide present in an extended-release form and a thiazolidinedione present in an immediate-release form. The present invention further relates to the processes for preparing such compositions. | 04-19-2012 |
| 20120071649 | PROCESS FOR THE PREPARATION OF QUETIAPINE FUMARATE - The present invention relates to an improved process for the preparation of quetiapine and pharmaceutically acceptable salts. It also relates to improved process for the preparation of intermediates of quetiapine. | 03-22-2012 |
| 20120029208 | PROCESS FOR (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4- [(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3, 5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT - The present invention relates to processes for the manufacture of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol- | 02-02-2012 |
| 20120004462 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE - The present invention is concerned with novel compounds and their use for the preparation of lacosamide. The present invention also contemplates processes for the preparation of lacosamide employing the novel compound of general Formula II, Formula IIa or Formula IIb as intermediate. | 01-05-2012 |
| 20120003307 | LEVETIRACETAM CONTROLLED RELEASE COMPOSITION - The present invention is concerned with controlled release compositions for oral administration comprising levetiracetam; and with processes of preparing such controlled release compositions. | 01-05-2012 |
| 20110236494 | CIPROFLOXACIN ORAL SUSPENSION - The present invention relates to oral taste masked pharmaceutical composition comprising ciprofloxacin or salts or esters thereof. It further relates to processes of preparing it. | 09-29-2011 |
| 20110224435 | PROCESS FOR PREPARATION OF AMORPHOUS LOPINAVIR - The present invention relates to a process for preparation of amorphous lopinavir, which is HIV protease inhibitor of Formula (I). Using agitated film drying. | 09-15-2011 |
| 20110217369 | FENOFIBRATE COMPOSITIONS - The present invention relates to a fenofibrate composition comprising: fenofibrate, a surfactant, a hydrophilic polymer and one or more anti-foaming agents. The invention also relates to a novel process for preparing said composition that has enhanced dissolution and absorption characteristics. | 09-08-2011 |
| 20110207933 | PROCESS FOR THE PREPARATION OF ZIPRASIDONE - The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia. | 08-25-2011 |
| 20110190369 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors - The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms. | 08-04-2011 |
| 20110190296 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors - The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms. | 08-04-2011 |
| 20110178305 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF - The present invention relates to a process for the preparation of threo-3,4-epoxy-2-amino-1-substituted butane derivatives represented by general Formula I which comprises reacting compound of Formula III or salt thereof with an active ester of acid of Formula IV and treating the product thereof with base. The carbon atom bonded to the radical R | 07-21-2011 |
| 20110172201 | PROCESS FOR PREPARING A CARBAPENEM ANTIBIOTIC COMPOSITION - The present invention relates to a process for preparing a carbapenem antibiotic composition. The present invention further relates to a carbapenem antibiotic composition substantially free of degradation impurities. The present invention further relates to a polymorphic form of ertapenem mono sodium designated as Form D and its preparation. | 07-14-2011 |
| 20110166088 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS - The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, | 07-07-2011 |
| 20110130403 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed hereinf having the structure of Formula I: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE t e 4/PDE t e 7 inhibitors are rovided. | 06-02-2011 |
| 20110124886 | PROCESS FOR THE PREPARATION OF DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS (OZ277) - This invention relates to an improved process for the preparation of a compound of Formula (I), salts of the free base cis-adamantane-2-spiro-3′-8′-[[[(2′-amino-2′-methyl propyl)amino]carbonyl]methyl]-1′,2′,4′-trioxaspiro[4.5]decane wherein X can be an anion. | 05-26-2011 |
| 20110082293 | PROCESS FOR THE PREPARATION OF STERILE DORIPENEM - The present invention relates to a process for the preparation of sterile doripenem. | 04-07-2011 |
| 20110071287 | PROCESS FOR THE PREPARATION OF EFAVIRENZ - The present invention relates to a process for the preparation of Efavirenz (Formula I), wherein triphosgene is used as a cyclizing agent. | 03-24-2011 |
| 20110052686 | MODIFIED RELEASE LAMOTRIGINE TABLETS - The present invention relates to uncoated modified-release tablets of lamotrigine and the process for preparation thereof, wherein the tablets comprise a portion of lamotrigine in an admixture with a pH-dependent polymer. | 03-03-2011 |
| 20110034690 | PROCESS FOR THE PREPARATION OF PURE PRULIFLOXACIN - The present invention relates to a process for the preparation of prulifloxacin. The present invention further relates to prulifloxacin having purity of about 99% or above. | 02-10-2011 |
| 20110034489 | SOLID DOSAGE FORMS OF HIV PROTEASE INHIBITORS - The present invention relates to a solid dosage form comprising a solid dispersion composition of at least one HIV protease inhibitor and water soluble polymer having a glass transition temperature (Tg) of at least about 50° C. in an amount of less than 50% by weight of the dosage form. It also relates to a process of preparation of such solid dosage forms. | 02-10-2011 |
| 20110020408 | MULTILAYERED MODIFIED RELEASE FORMULATION COMPRISING AMOXICILLIN AND CLAVULANATE - The present invention relates to multilayered modified release formulation comprising amoxicillin and clavulanate, process of preparation thereof and method of treating bacterial infection using these formulations. The multilayered modified release formulation comprises: an immediate release layer comprising amoxicillin and clavulanate; and a slow release layer comprising amoxicillin and one or more release retarding agents; and one or more non-release controlling inert barrier layers placed in between the immediate release layer and the slow release layer and comprising one or more pharmaceutically acceptable excipients. | 01-27-2011 |
| 20100324290 | CRYSTALLINE FORM I OF LAMIVUDINE AND ITS PREPARATION - The present invention relates to a stable crystalline Form I of lamivudine. The present invention further relates to a process for the preparation of the stable crystalline Form (I) of the stable crystalline Form (I) of lamivudine. | 12-23-2010 |
| 20100311961 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 1,3-OXATHIOLANES, ESPECIALLY LAMIVUDINE - The present invention relates to process and intermediates for the preparation of substituted 1,3-oxathiolanes. The present invention specifically relates to a process for the preparation of lamivudine. | 12-09-2010 |
| 20100305328 | PROCESS FOR PREPARATION OF PIPERIDINE CARBOXYLIC ACID - Processes for preparing pure tiagabine, a piperidine carboxylic acid, using pharmaceutically acceptable acid addition salts of tiagabine esters are provided. L(+)-tartaric acid, oxalic acid and dibenzoyl L(+)-tartaric acid addition salts of tiagabine esters are also provided. Further, processes for preparing acid addition salts of tiagabine esters are provided. | 12-02-2010 |
| 20100297195 | CONTROLLED RELEASE LAMOTRIGINE FORMULATIONS - The present invention relates to controlled release formulations comprising lamotrigine and process for preparation thereof. | 11-25-2010 |
| 20100292196 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided. | 11-18-2010 |
| 20100280093 | PROCESS FOR THE PREPARATION ENANTIOMERICALLY PURE SALTS OF N-METHYL-3-(1-NAPHTHALENEOXY)-3-(2-THIENYL)PROPANAMINE - The present invention relates to duloxetine salts having enantiomeric purity of 98% or more and a process for such salts. | 11-04-2010 |
| 20100268187 | PACKAGING FOR SIROLIMUS AND COMPOSITION THEREOF - The present invention relates to a packaging kit used for the stabilization of sirolimus particles wherein the packaging kit is in the form of a vacuum sealed impermeable container. It further relates to a method for stabilization of sirolimus particles as well as composition comprising the particles. | 10-21-2010 |
| 20100247646 | EXTENDED RELEASE TABLETS OF NISOLDIPINE - The present invention relates to extended release tablets comprising a core which comprises of nisoldipine, a rate-controlling hydrophilic polymer and optionally, an enteric agent. Such tablets may also be coated with a release rate-controlling coating comprising of a hydrophobic polymer or enteric agent or combinations thereof, in particular ethylcellulose, and Eudragits. | 09-30-2010 |
| 20100228030 | PROCESS FOR THE PREPARATION OF INTERMEDIATES OF TETRACYCLIC COMPOUNDS - The present invention relates to a process for the preparation of cis-intermediates of Formula II, (Formula II) wherein R1 represents hydrogen, (un)substituted alkyl, alkenyl, aryl, and X represents a leaving group, which are useful synthetic intermediates in the preparation of tetracyclic compounds having phosphodiesterase inhibitory activity. | 09-09-2010 |
| 20100210847 | PROCESS FOR THE PREPARATION OF PANTOPRAZOLE SODIUM AND PANTOPRAZOLE SODIUM SESQUIHYDRATE - The present invention relates to a process for the preparation of pantoprazol sodium sesquihydrate of formula (I) and pantoprazole sodium. | 08-19-2010 |
| 20100178341 | BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR - The present invention relates to a bilayered tablet comprising: a slow release layer comprising niacin and release retarding agent; and an immediate release layer comprising HMG-CoA reductase inhibitor. | 07-15-2010 |
| 20100178338 | STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING ATORVASTATIN - This invention relates to stabilized pharmaceutical compositions comprising atorvastatin or pharmaceutically acceptable salts thereof, and processes for the preparation of the same. | 07-15-2010 |
| 20100152269 | MODIFIED-RELEASE FORMULATIONS OF AZABICYCLO DERIVATIVES - The present invention discloses modified-release oral dosage forms of an azabicyclo derivative or its pharmaceutically acceptable salts, solvates, esters, enantiomers, diastereomers, N-oxides and polymorphs; and processes for the preparation thereof. The modified release formulation comprises an azabicyclo derivative, at least one rate-controlling polymer and at least one pharmaceutically acceptable excipient which provides therapeutically effective plasma levels of the active ingredient for a period of up to 24 hours. | 06-17-2010 |
| 20100145099 | NOVEL POLYMORPHIC FORMS OF MILNACIPRAN HYDROCHLORIDE - The present invention relates to polymorphic forms of milnacipran hydrochloride. The polymorphic forms are designated as Form (I), Form (II), Form (III), Form (IV) and Form V of milnacipran hydrochloride. The present invention also relates to processes for the preparation of the polymorphic forms. | 06-10-2010 |
| 20100144800 | EXTENDED RELEASE TABLET FORMULATION OF NIACIN - The present invention relates to an extended release tablet formulation comprising niacin and a release retarding agent selected from hydroxypropyl cellulose, polyethylene oxide or mixtures thereof. | 06-10-2010 |
| 20100120902 | STANDARIZED BIOACTIVE HERBAL EXTRACTS - The present invention relates to standardized extracts of | 05-13-2010 |
| 20100113783 | PROCESS FOR THE PREPARATION OF CRYSTALS OF PRULIFLOXACIN - The present invention relates to processes for the preparation of Type I, Type II and Type III crystals of prulifloxacin. | 05-06-2010 |
| 20100099776 | OILY SUSPENSION OF ATOVAQUONE - The present invention relates to an oily suspension of atovaquone comprising atovaquone particles and a combination of surfactants having HLB more than 10. | 04-22-2010 |
| 20100029728 | PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of CNS diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and their use as PDE type IV selective inhibitors, are provided. | 02-04-2010 |
| 20090326004 | MUSCARINIC RECEPTOR ANTAGONISTS - The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors. | 12-31-2009 |
| 20090118520 | PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT - The present invention relates to processes for the preparation of (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt. | 05-07-2009 |
| 20090105221 | MUSCARINIC RECEPTOR ANTAGONISTS - This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. | 04-23-2009 |
| 20090036680 | SALTS OF HMG-COA REDUCTASE INHIBITORS AND USE THEREOF - The present invention relates to salts of HMG CoA reductase inhibitors, and in particular, rosuvastatin amine salts and their use as intermediates in the preparation of rosuvastatin calcium. | 02-05-2009 |
| 20080319002 | Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists - This present invention generally relates to xanthine derivatives as muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. | 12-25-2008 |
| 20080312254 | Process for the Preparation of Ziprasidone - The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia. | 12-18-2008 |
| 20080305158 | Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine - The present invention relates to pharmaceutical compositions comprising amlodipine and pharmaceutically acceptable salts thereof, and atorvastatin and pharmaceutically acceptable salts thereof, and processes for their preparation. | 12-11-2008 |
| 20080287690 | Process For (3R, 5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4- [(4-Hydroxy Methyl Phenyl Amino) Carbonyl]-Pyrrol-1-Yl]-3,5-Dihydroxy-Heptanoic Acid Hemi Calcium Salt - The present invention relates to processes for the manufacture of (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt. | 11-20-2008 |
| 20080287376 | Ketolide Derivatives as Antibacterial Agents - The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, | 11-20-2008 |
| 20080262075 | Pyrrolidine Derivatives as Muscarinic Receptor Antagonists - This invention relates to pyrrolidine derivatives, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Processes for the preparation of described compounds, pharmaceutical compositions containing the described compounds and the methods for treating the diseases mediated through muscarinic receptors are also provided. | 10-23-2008 |
| 20080207536 | Antibacterial Agents - The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against bacterium such as | 08-28-2008 |
